TradingViewTradingView

United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary

Moins d'1 minute de lecture

United-Guardian's revenue rose 54% and earnings increased year over year, with sales gains across pharmaceuticals, cosmetic ingredients and medical lubricants. Renacidin formulary coverage contributed to pharmaceutical growth, while increased purchases by ASI after its 2025 overstock situation drove cosmetic ingredient sales.

Financial Highlights

MetricCurrent quarterPrior year quarterYoY change
Revenue¹$3.49M$2.26M54.3%
Net income²$930.91K$268.44K246.8%
Diluted EPS³$0.2$0.06233.3%

¹ Reported as “Net sales”. ² Reported as “Net income”. ³ Reported as “Earnings per common share (Basic and Diluted)”.

Business Highlights

  • Pharmaceuticals: Net sales rose 29%; Renacidin formulary coverage and higher Clorpactin WCS-90 orders contributed to the increase.
  • Cosmetic ingredients: Sales climbed 187%, primarily as ASI resumed regular purchases following its 2025 overstock situation.
  • Medical lubricants: Sales increased 20%, driven by higher orders from a large customer in India.
  • Cost of sales: Fell to 46% of sales from 58%, reflecting lower per-unit overhead costs from increased production.

Original SEC Filing: UNITED GUARDIAN INC [ UG ] - 10-Q - Nov. 12, 2026

Clause de non-responsabilité